| 0.7751 0.005 (0.65%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.48 |
1-year : | 1.86 |
| Resists | First : | 1.27 |
Second : | 1.6 |
| Pivot price | 0.99 |
|||
| Supports | First : | 0.75 |
Second : | 0.62 |
| MAs | MA(5) : | 0.89 |
MA(20) : | 1.06 |
| MA(100) : | 0.87 |
MA(250) : | 0.91  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.6 |
D(3) : | 6.5 |
| RSI | RSI(14): 35.2 |
|||
| 52-week | High : | 1.6 | Low : | 0.64 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ DYAI ] has closed below the lower bollinger band by 3.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 54.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.81 - 0.82 | 0.82 - 0.82 |
| Low: | 0.74 - 0.74 | 0.74 - 0.75 |
| Close: | 0.77 - 0.78 | 0.78 - 0.78 |
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.
Fri, 14 Aug 2026
Dyadic International Raises $2.9 Million in Registered Direct and Concurrent Warrant Offering - TradingView
Fri, 14 Aug 2026
Dyadic International (NASDAQ: DYAI) prices $2.9M stock sale and warrant placement - Stock Titan
Thu, 13 Aug 2026
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
Wed, 12 Aug 2026
Earnings call transcript: Dyadic International Q2 2026 revenue beats, shares fall 16% - Investing.com
Wed, 12 Aug 2026
Dyadic reports Q2 2026 net loss of $2.12M on $0.96M revenue; cash ~$4.79M - TradingView
Wed, 12 Aug 2026
Dyadic Applied BioSolutions Q2 2026: Revenue $961K, EPS $(0.06) — 10-Q Summary - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 3.233e+007 (%) |
| Held by Institutions | 25.2 (%) |
| Shares Short | 148 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -191.5 % |
| Operating Margin | -172.2 % |
| Return on Assets (ttm) | -56.3 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 3.81e+006 % |
| Gross Profit (p.s.) | 178.72 |
| Sales Per Share | 810.7 |
| EBITDA (p.s.) | 974206 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -79.07 |
| Dividend | 0 |
| Forward Dividend | 83530 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|